Huiyu Pharmaceuticals (688553.SH): Methotrexate injection obtains drug registration certificate.

Huiyu Pharmaceutical (688553.SH) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for methotrexate injection. Methotrexate can inhibit dihydrofolate reductase. Dihydrofolate must be reduced to tetrahydrofolate by this enzyme in order to serve as a carrier for one-carbon units in the synthesis of purine nucleotides and thymidine nucleotides. Therefore, methotrexate interferes with DNA synthesis, repair, and cell replication. Proliferating tissues such as malignant tumor cells, bone marrow, embryonic cells, oral and intestinal mucosa, and bladder cells are typically more sensitive to the effects of methotrexate. Methotrexate has broad-spectrum anti-tumor activity and can be used to treat breast cancer, gestational trophoblastic neoplasia, osteosarcoma, acute leukemia, bronchial lung cancer, head and neck squamous cell carcinoma as a single agent or in combination with other chemotherapy drugs. It can also be used in high doses alone or in combination with other chemotherapy drugs to treat osteosarcoma, acute leukemia, bronchial lung cancer, head and neck squamous cell carcinoma, and for chemotherapy in psoriasis.